On June 26, Abivax S.A. fell 5.38% in after-hours trading, trading at $92.37/share, with turnover of $247,000.

On the news front, the ongoing safety controversy surrounding the company's core drug obefazimod continues to weigh on the stock. The Phase 3 ABTECT maintenance trial previously reported multiple cancer cases in the 50mg dosing group, triggering a sharp decline from approximately $130 to around $70 — a drop of nearly 50%. While some investors subsequently argued the cancer cases were more likely age-related, prompting a partial recovery above $100, market consensus on the safety issue remains unresolved. Technical rebound momentum has progressively weakened, with the stock resuming its downtrend over recent sessions.

Within the Biotechnology sector, AbbVie down 0.18%, Revolution Medicines unchanged, Gilead Sciences up 0.5%, Amgen up 0.65%, Ascendis Pharma unchanged.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)